Log in

NASDAQ:TTPHTetraphase Pharmaceuticals Stock Price, Forecast & News

+0.34 (+14.78 %)
(As of 05/25/2020 04:00 PM ET)
Today's Range
Now: $2.64
50-Day Range
MA: $1.58
52-Week Range
Now: $2.64
Volume18.06 million shs
Average Volume1.11 million shs
Market Capitalization$19.17 million
P/E RatioN/A
Dividend YieldN/A
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Read More
Tetraphase Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TTPH



Sales & Book Value

Annual Sales$7.38 million
Book Value$6.68 per share


Net Income$-70,080,000.00
Net Margins-798.18%


Market Cap$19.17 million
Next Earnings Date8/13/2020 (Estimated)

Receive TTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions

How has Tetraphase Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Tetraphase Pharmaceuticals' stock was trading at $1.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TTPH shares have increased by 68.2% and is now trading at $2.64. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tetraphase Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tetraphase Pharmaceuticals.

When is Tetraphase Pharmaceuticals' next earnings date?

Tetraphase Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tetraphase Pharmaceuticals.

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.63) by $0.32. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $2.45 million. Tetraphase Pharmaceuticals had a negative return on equity of 210.86% and a negative net margin of 798.18%. View Tetraphase Pharmaceuticals' earnings history.

When did Tetraphase Pharmaceuticals' stock split? How did Tetraphase Pharmaceuticals' stock split work?

Shares of Tetraphase Pharmaceuticals reverse split on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019. An investor that had 100 shares of Tetraphase Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for TTPH?

4 brokerages have issued 12 month price objectives for Tetraphase Pharmaceuticals' shares. Their forecasts range from $40.00 to $40.00. On average, they expect Tetraphase Pharmaceuticals' stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 1,415.2% from the stock's current price. View analysts' price targets for Tetraphase Pharmaceuticals.

What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?

Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (5/23/2020)
  • 2. HC Wainwright analysts commented, "We are reiterating our Hold rating on PCRX shares after the company reported 2Q19 Exparel sales which were in-line with consensus. Given 3Q tends to be a low Q/Q growth quarter due to seasonality, we think this sets up the need for a big 4Q19 Exparel sales number for the company to beat guidance and for shares to meaningfully outperform. Additionally, we would expect shares to be volatile around updates from competitors HRTX (Buy, $17.87) and DRRX (Adam Walsh, Hold, $1.43) which we expect in the coming months – with positive updates from one or both weighing on shares. Overall, we continue to remain on the sidelines as we think shares seem fairly valued at these levels and the potential for incoming competition in the next ~6-12 months poses a headwind, in our view. Key Points Exparel sales met 2Q19 expectations and FY19 Exparel sales guidance was reiterated." (8/11/2019)

Has Tetraphase Pharmaceuticals been receiving favorable news coverage?

News stories about TTPH stock have trended extremely negative recently, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tetraphase Pharmaceuticals earned a media sentiment score of -4.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutTetraphase Pharmaceuticals.

Are investors shorting Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 92,800 shares, a decrease of 29.8% from the April 30th total of 132,200 shares. Based on an average daily volume of 1,070,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.4% of the shares of the company are sold short. View Tetraphase Pharmaceuticals' Current Options Chain.

Who are some of Tetraphase Pharmaceuticals' key competitors?

What other stocks do shareholders of Tetraphase Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), Bank of America (BAC), Opko Health (OPK), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Rite Aid (RAD), Melinta Therapeutics (MLNT) and Exelixis (EXEL).

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the following people:
  • Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 60)
  • Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 54)
  • Dr. Jacques Dumas, Chief Scientific Officer (Age 53)
  • Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 48)
  • Mr. Larry G. Edwards, Chief Operating Officer (Age 47)

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

Who are Tetraphase Pharmaceuticals' major shareholders?

Tetraphase Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sabby Management LLC (9.18%), BlackRock Inc. (0.96%) and Bank of New York Mellon Corp (0.39%). Company insiders that own Tetraphase Pharmaceuticals stock include Guy Macdonald, Jacques Dumas and John Gordon Freund. View institutional ownership trends for Tetraphase Pharmaceuticals.

Which institutional investors are buying Tetraphase Pharmaceuticals stock?

TTPH stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, Bank of New York Mellon Corp, and BlackRock Inc.. View insider buying and selling activity for Tetraphase Pharmaceuticals.

How do I buy shares of Tetraphase Pharmaceuticals?

Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of TTPH stock can currently be purchased for approximately $2.64.

How big of a company is Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals has a market capitalization of $19.17 million and generates $7.38 million in revenue each year. The biopharmaceutical company earns $-70,080,000.00 in net income (profit) each year or ($22.85) on an earnings per share basis. Tetraphase Pharmaceuticals employs 119 workers across the globe.

What is Tetraphase Pharmaceuticals' official website?

The official website for Tetraphase Pharmaceuticals is www.tphase.com.

How can I contact Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL WAY, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.